Annual Reports

For 100 years, CSL has earned a reputation as a passionate yet responsible organization that is driven to care for patients and deliver on its commitments. Today, our future has never looked brighter. We expect that emerging new innovations and support programs can provide unprecedented opportunities to improve patient wellbeing unlike any other time in history.

View archived annual reports

Key Business Highlights

CSL continues to deliver on its strategy, with an 11%# increase in total revenue. The strength of our results reflects the execution of our strategic plan and patient-focussed workforce.

   

bargraph icon

Strategic Objective

GROWTH

Maximize portfolio value & deliver new product launches

Immunoglobulin sales up by 11%# on the prior comparable period.

IDELVION®, recombinant coagulation factor for the treatment of haemophilia B, sales exceeded forecast and is the market leader in a number of countries.

Specialty products portfolio grew by 24%# driven by strong performance in KCENTRA® and HAEGARDA®, which achieved nearly 50% of the prophylaxis hereditary angioedema (HAE) market in the United States (US).

Exercised the option to acquire 100% of Chinese plasma fractionator.


cog icon

Strategic Objective

EFFICIENCY

Be the most efficient, highest quality plasma player

CSL Plasma opens 27 new collection centres in the US – a growth rate unmatched in the industry. Across the US and Europe, CSL Plasma now holds more than 200 collection centres.

Launch of a new CSL Plasma donor management system.

Investments in large-scale Group-wide capital initiatives, across all regions, remain on track.



medical bag icon

Strategic Objective

INFLUENZA

Delivery on influenza strategy

Seqirus delivers on its commitment to achieve profitability just three years after the business was formed.

Influenza sales grew 53%#, with FLUAD, an adjuvanted influenza vaccine, reporting sales up by 142%#.

The Holly Springs facility in the US, which utilises innovative cell-based technology, quadrupled the number of FLUCELVAX® QUADRIVALENT influenza vaccine doses for the US market.



annual report innovation icon

Strategic Objective

INNOVATION

Pursue new opportunities to diversify portfolio and enhance growth

Approval of immunoglobulin products PRIVIGEN®, in the US, and HIZENTRA®, in the US and Europe, provides patients with a convenient treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

Acquisition of Calimmune provides CSL with a promising gene therapy platform.

CSL and Vitaeris announce strategic partnership to support an emerging transplant portfolio.

CSL112, our cardiovascular disease product, moves into Phase III clinical trial.



annual report people icon

Strategic Objective

PEOPLE & CULTURE

Create a culture that attracts, retains and develops the best talent

Named one of the world’s Top 50 employers by Forbes (2017) Global 2000: World’s Best Employers.

Total workforce continues to grow, achieving employee engagement index scores higher than the global IBM norms.

New people manager programs launched to develop skills and capabilities at every stage of their career.


# Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to CSL’s Financial Statements for the Full Year ended 2018 (Directors’ Report).

Annual Report Archive

This archive features CSL Limited's Annual Reports between 2013 and 2018



Product Pipeline

Delve into our portfolio of new products, improved products and manufacturing expertise.

Learn More
Stock Information

Track recent and historical movements of CSL's stock price on the Australian Securities Exchange.

Learn More
Financial Results and Information

See how our performance is a result of a focused strategy.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter